Circulating stem cell vary with NYHA stage in heart failure patients.
Bottom Line: Compared with healthy individuals, MSC, and in particular the sub-classes CD45(-) CD34(-) CD90(+) , CD45(-) CD34(-) CD105(+) and CD45(-) CD34(-) CXCR4(+) were significantly enhanced in NYHA class IV patients (16.8-, 6.4- and 2.7-fold, respectively).Level of CD45(-) CD34(-) CD90(+) CXCR4(+) cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively).Both the entity and kinetic of this process varied in distinct cell subsets.
Affiliation: University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: Conversely, HSCs (Fig. 3), although significantly augmented in patients with respect to controls, did not show a significant trend to increase with NYHA class. Emblematically, the fraction characterized as CD45+CD34+CD90+ expressing the CXCR4 receptor (Fig. 3C), peaks in class III patients and returns to control level in class IV. CD45+CD34+CD105+ cells expressing the CXCR4 and CD45+CD34+ cells expressing PDGFR were also increased in patients (Fig. 3D and E).
Affiliation: University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy. email@example.com